State-specific inhibition of NMDA receptors by memantine provides insight into NMDAR channel blocker tolerability

Matthew B. Phillips, Nadya V. Povysheva, Elizabeth G. Neureiter, Aparna Nigam, Karen A. Harnett-Scott, Johannes W. Hell, Elias Aizenman, Jon W. Johnson · 2026

Read State-specific inhibition of NMDA receptors by memantine provides insight into NMDAR channel blocker tolerability by Matthew B. Phillips, Nadya V. Povysheva, Elizabeth G. Neureiter, Aparna Nigam, Karen A. Harnett-Scott, Johannes W. Hell, Elias Aizenman, Jon W. Johnson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13215171.txt.

Description

Matthew B. Phillips and colleagues ask in 2026 why two drugs that block the same brain receptor feel so unlike in patients. Both memantine, used for Alzheimer's disease, and ketamine plug a channel that lets calcium into nerve cells. Too much calcium harms cells, yet memantine is gentle while ketamine has strong side effects.

In lab tests on made and native receptors, memantine's block grew as calcium inside the cell rose. Ketamine's block did not. High calcium locks the receptor in a rest state, and memantine holds it there. The effect shifts with receptor subtype. In harm tests, memantine shut down receptors most where calcium ran high and damage loomed. Aiming at sick circuits, not all circuits, may explain its kinder profile.

Catalog record

CREATORMatthew B. Phillips, Nadya V. Povysheva, Elizabeth G. Neureiter, Aparna Nigam, Karen A. Harnett-Scott, Johannes W. Hell, Elias Aizenman, Jon W. Johnson
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE87 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13215171

Browse the full library · About the Tower of Babel